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Purpose/Objective: This randomized phase III trial compared 
clinical outcome of concurrent chemoradiotherapy (CCRT) 
versus neoadjuvant chemotherapy plus radiotherapy (NeoCT-
RT) in patients with advanced nasopharygeal carcinoma 
(NPC). 
Materials and Methods: A total of 256 NPC patients with 
2002 AJCC stage II-IVB were randomized to CCRT or NeoCT-
RT. Both arms received IMRT with similar dosage and 
fractionation. The regimen of chemotherapy were concurrent 
PF (two cycles of concurrent chemotherapy with cisplatin 20 
mg/m2/day + 5-fluorouracil 400 mg/m2/day, 96-hour 
continuous infusion during the first and 5th week) or 
neoadjuvant P-FL (cisplatin 60 mg/m2 D1 and 5-FU 2500 
mg/m2 + Leucovorin 250 mg/m2 D8, repeated every 2 weeks 
for 5 cycles). Post-radiation adjuvant chemotherapy using 
oral tegafur-uracil was recommended to patients with high-
risk factors for one year in both arms. 
Results: Baseline patient characteristics were comparable in 
both arms. NeoCT-RT has better Complete response rates, 
evaluated 2-3 months after radiotherapy than CCRT (96.1% 
vs. 85.0%, P=0.0047). Acute toxicity during radiotherapy 
period revealed a significant reduction of grade 3/4 
nausea/vomiting, mucositis, dermatitis, and weight loss in 
the NeoCT-RT arm. After a minimal follow-up of 60 months, 
26.8% (34/127) and 23.3% (30/129) patients in CCRT and Neo-
RT groups developed tumor relapse respectively. The overall 
survival (5-year rate, 81.6% vs. 85.3%, P=0.1967) and 
progression-free survival (5-year rate, 74.0% vs. 78.9%, 
P=0.3807) were similar in both arms. 
Conclusions: NeoCT-RT has a higher initial complete 
response rate and less grade 3/4 acute toxicities during 
radiotherapy but has similar survivals compared with CCRT in 
patients with advanced NPC.  
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Purpose/Objective: There are established guidelines for 
baseline diagnosis and post treatment surveillance among 
head and neck cancer (HNC) patients with PETCT parameters 
like standardized uptake value (SUV), metabolic tumor 
volume (MTV) and Total lesion glycolysis (TLG). The same 
remains controversial and experimental among post 
irradiation (RT) recurrence especially with SBRT. We 
analyzed the PETCT parameters correlating response and 
survival among post RT recurrent HNC (rHNC) undergoing 
Cyberknife SBRT. 
Materials and Methods: Thirteen (10 male and 3 female) HNC 
patients with post RT recurrence undergoing Cyberknife SBRT 
were analyzed. Six patients had loco-regional recurrences, 
five had nodal while one each had distant nodal and 2nd 
primary HNC. All patients had post treatment follow up PET 
scan and on suspicion had biopsy/FNAC proved recurrences. 
All patients received Cyberknife SBRT alone with median dose 
per fraction 6 Gy (5-12 Gy) in 5 fractions (3-7 fractions). Pre 
Cyberknife median SUVmax, MTV and TLG were calculated 
using custom-designed software. Post Cyberknife at 10-12 
weeks the similar values were recorded again. At the time of 
analysis the last follow up status, objective response and 
median values of PET parameters were used as cutoffs while 
assessing their prognostic potential through Chi sqaure test, 
Cox regression analyses, ROC analysis and Pearson's 
correlation respectively. 
Results: The median values of PETCT SUVmax, MTV and TLG 
pre and post therapy were 14.5/6.19, 25.5/1.43 and 
155.03/7.42 respectively. The median reduction in SUV, MTV 
and TLG pre and post Cyberknife were 21.1, 69.2 and 72.8% 
respectively. With a median gap of 18 months (3-77 months) 
between 1st and 2nd RT, the median recurrent gross tumor 
volume (GTV) was 32.6 cc (9.2-243 cc). The median follow up 
post reRT was 9 months (4-19 months) and 6/13 patients had 
loco-regionally stable disease. 
Chi square test and likelihood ratios between median pre 
therapy SUVmax, MTV and TLG with post Cyberknife response 
showed median pre therapy MTV to be statistically significant 
(p=0.04). The likelihood ratios for median reduction in 
SUVmax, MTV and TLG and post CK response also revealed 
MTV and TLG to be closer to statistical significance (p=0.06). 
There was positive correlation between median PETCT 
parameters and median GTV volumes though statistically not 
significant, but pre therapy median MTV values were most 
important in predicting response. 
Both univariate and multivariate analysis suggested trend 
towards better survival in groups with lower MTV and TLG 
values pre and post therapy. ROC analysis though was not 
sensitive to detect MTV and TLG parameters with survival. 
Conclusions: PETCT parameters like MTV and TLG other than 
SUVmax has definite role among rHNC undergoing Cyberknife 
SBRT. Future prospective studies with larger population and 
serial measurement of SUV, MTV and TLG might actually 
establish predictive cut-off values for response and survival. 
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Purpose/Objective: 18FDG PET-CT is a useful test not only for 
diagnosis, staging, evaluation of treatment response or follow 
up in head and neck cancer (HNC), but either can provide 
important complementary information for radiotherapy 
planning. The aim of this study is to investigate the potential 
impact of using 18FDG PET-CT on radiotherapy target volume 
delineation for HNC through the experience at our Center. 
